How many drugs treat Dacryocystitis?

Drug Landscape tracks 8 marketed treatments for Dacryocystitis (deduplicated by molecule). 0 Phase 3 candidates and 0 Phase 2 candidates are in the pipeline.

How do I subscribe to ongoing alerts?

Subscribe to /feed/disease/dacryocystitis.xml in Feedly / Inoreader. Every regulatory action, PDUFA date, or trial completion in this treatment area lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Dacryocystitis — Treatment Landscape & Competitive Intelligence

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Dacryocystitis (disease) competitive landscape: 8 marketed treatments tracked, 0 Phase 3 candidates, 0 Phase 2 candidates. Recent regulatory actions and upcoming PDUFA dates across the entire treatment set.

8 marketed 0 Phase 3 0 Phase 2 Live · 30-min refresh

Marketed treatment landscape

Approved drugs treating Dacryocystitis, deduplicated by molecule. See the full disease page for line-of-therapy detail.

Drug	Generic	Sponsor	Class	Target	First approval
Zithromax	azithromycin	Pfizer Inc.	Macrolide antibiotic (azalide)	Canalicular multispecific organic anion transporter 1, Taste receptor type 2 member 4, Motilin receptor	1991-11-01
Vantobra	Tobramycin Sulfate	Pfizer	tobramycin	Taste receptor type 2 member 20	1974-01-01
Gentamicin	Gentamicin Sulfate	Merck & Co.	gentamicin	Dihydrofolate reductase	1970-01-01
Garamycin	GENTAMICIN	Merck & Co.	Aminoglycoside Antibacterial	Transient receptor potential cation channel subfamily V member 5	1970-01-01
Prelone	prednisolone	Generic (originally Schering)	Glucocorticoid (corticosteroid)	Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1	1955-01-01
prednisolon	prednisolon	Hannover Medical School		Annexin A1, Corticosteroid-binding globulin, G-protein coupled bile acid receptor 1
Tobi	tobramycin	Novartis		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)
Nebcin	Nebcin	University Hospital, Lille		Taste receptor type 2 member 20, Macrolide 2'-phosphotransferase II; Macrolide 2'-phosphotransferase II protein MphB; Macrolide 2-phosphotransferase, mph(B)

Phase 3 pipeline

No Phase 3 pipeline candidates tracked.

Phase 2 pipeline

No Phase 2 pipeline candidates tracked.

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this treatment set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this treatment set.

Sponsor landscape

Merck & Co. · 2 drugs in Dacryocystitis
Generic (originally Schering) · 1 drug in Dacryocystitis
Hannover Medical School · 1 drug in Dacryocystitis
Novartis · 1 drug in Dacryocystitis
Pfizer · 1 drug in Dacryocystitis
Pfizer Inc. · 1 drug in Dacryocystitis
· 1 drug in Dacryocystitis
University Hospital, Lille · 1 drug in Dacryocystitis

Subscribe to ongoing alerts

Every new regulatory action, PDUFA date, or trial completion in Dacryocystitis:

Cite this brief

Drug Landscape (2026). Dacryocystitis — Treatment Landscape & Competitive Intelligence Brief. https://druglandscape.com/ci/disease/dacryocystitis. Accessed 2026-06-10.

Dacryocystitis full disease profile — treatment pathway, diagnostics, guidelines
Browse all CI briefs
Build a custom feed

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing